Search Results - "de Wreede, L."

Sensitivity of hematological malignancies to graft-versus-host effects: an EBMT megafile analysis by Stern, M, de Wreede, L C, Brand, R, van Biezen, A, Dreger, P, Mohty, M, de Witte, T M, Kröger, N, Ruutu, T

“…After allogeneic stem cell transplantation, graft-versus-host disease (GvHD) occurs through recognition of histocompatibility mismatches by donor T…”
Get full text

Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT by Ruutu, T, de Wreede, L C, van Biezen, A, Brand, R, Mohty, M, Dreger, P, Duarte, R, Peters, C, Garderet, L, Schönland, S, Gratwohl, A, Niederwieser, D, de Witte, T, Kröger, N

“…In patients treated with allogeneic stem cell transplantation (SCT) for malignant disease who suffer from a relapse after the transplantation, the role of…”
Get full text

Risk factors for treatment failure after allogeneic transplantation of patients with CLL: a report from the European Society for Blood and Marrow Transplantation by Schetelig, J, de Wreede, L C, van Gelder, M, Andersen, N S, Moreno, C, Vitek, A, Karas, M, Michallet, M, Machaczka, M, Gramatzki, M, Beelen, D, Finke, J, Delgado, J, Volin, L, Passweg, J, Dreger, P, Henseler, A, van Biezen, A, Bornhäuser, M, Schönland, S O, Kröger, N

“…For young patients with high-risk CLL, BTK-/PI3K-inhibitors or allogeneic stem cell transplantation (alloHCT) are considered. Patients with a low risk of…”
Get full text

Trends in allogeneic haematopoietic cell transplantation for myelofibrosis in Europe between 1995 and 2018: a CMWP of EBMT retrospective analysis by McLornan, D., Eikema, D. J., Czerw, T., Kröger, N., Koster, L., Reinhardt, Hans Christian, Angelucci, E., Robin, M., Bornhäuser, M., Passweg, J., Clark, A., Vydra, J., Blau, I. E., Niittyvuopio, R., Platzbecker, U., Cornelissen, J. J., Chevallier, P., Srour, M., Stamatovic, D., Martinez-Lopez, J., de Wreede, L., Hayden, P., Hernández-Boluda, J. C., Yakoub-Agha, I.

“…We performed a retrospective assessment of patient- and transplant-specific characteristics and outcomes for 4142 patients undergoing allogeneic haematopoietic…”
Get full text

Allogeneic stem cell transplantation for older advanced MDS patients: improved survival with young unrelated donor in comparison with HLA-identical siblings by Kröger, N, Zabelina, T, de Wreede, L, Berger, J, Alchalby, H, van Biezen, A, Milpied, N, Volin, L, Mohty, M, Leblond, V, Blaise, D, Finke, J, Schaap, N, Robin, M, de Witte, T

“…We investigated whether a young human leukocyte antigen (HLA)-matched unrelated donor (MUD) should be preferred as donor to an HLA-identical sibling (MRD) for…”
Get full text

Sequential vs myeloablative vs reduced intensity conditioning for patients with myelodysplastic syndromes with an excess of blasts at time of allogeneic haematopoietic cell transplantation: a retrospective study by the chronic malignancies working party of the EBMT by Potter, V., Gras, L., Koster, L., Kroger, N., Sockel, K., Ganser, A., Finke, J., Labussiere-Wallet, H., Peffault de Latour, R., Koc, Y., Salmenniemi, U., Smidstrup Friis, L., Jindra, P., Schroeder, T., Tischer, J., Arat, M., Pascual Cascon, M., de Wreede, L. C., Hayden, P., Raj, K., Drozd-Sokolowska, J., Scheid, C., McLornan, D. P., Robin, M., Yakoub-Agha, I.

“…The optimal conditioning for patients with higher risk MDS receiving potentially curative allogeneic haematopoietic stem cell transplant(allo-HCT) remains to…”
Get full text

Comparison of conditioning regimens of various intensities for allogeneic hematopoietic SCT using HLA-identical sibling donors in AML and MDS with <10% BM blasts: a report from EBMT by Martino, R, de Wreede, L, Fiocco, M, van Biezen, A, von dem Borne, P A, Hamladji, R-M, Volin, L, Bornhäuser, M, Robin, M, Rocha, V, de Witte, T, Kröger, N, Mohty, M

“…In this multicenter retrospective study, the long-term outcomes of 878 adults with AML and refractory anemia with excess blasts (RAEB) with BM blasts <10% who…”
Get full text

Advantages of a multi-state approach in surgical research: how intermediate events and risk factor profile affect the prognosis of a patient with locally advanced rectal cancer by Manzini, G, Ettrich, T J, Kremer, M, Kornmann, M, Henne-Bruns, D, Eikema, D A, Schlattmann, P, de Wreede, L C

“…Standard survival analysis fails to give insight into what happens to a patient after a first outcome event (like first relapse of a disease). Multi-state…”
Get full text

Feasibility, safety, and efficacy of early prophylactic donor lymphocyte infusion after T cell-depleted allogeneic stem cell transplantation in acute leukemia patients by van der Zouwen, Boris, Koster, E. A. S., von dem Borne, P. A., Oosten, L. E. M., Roza-Scholten, M. W. I., Snijders, T. J. F., van Lammeren, D., van Balen, P., Marijt, W. A. F., Veelken, H., Falkenburg, J. H. F., de Wreede, L. C., Halkes, C. J. M.

“…Prophylactic donor lymphocyte infusion (DLI) starting at 6 months after T cell-depleted allogeneic stem cell transplantation (TCD-alloSCT) can introduce a…”
Get full text

Monosomal karyotype predicts poor survival after allogeneic stem cell transplantation in chromosome 7 abnormal myelodysplastic syndrome and secondary acute myeloid leukemia by van Gelder, M, de Wreede, L C, Schetelig, J, van Biezen, A, Volin, L, Maertens, J, Robin, M, Petersen, E, de Witte, T, Kröger, N

“…Treatment algorithms for poor cytogenetic-risk myelodysplastic syndrome (MDS), defined by chromosome 7 abnormalities or complex karyotype (CK), include…”
Get full text

Myeloablative T cell-depleted alloSCT with early sequential prophylactic donor lymphocyte infusion is an efficient and safe post-remission treatment for adult ALL by Eefting, M, Halkes, C J M, de Wreede, L C, van Pelt, C M, Kersting, S, Marijt, E W A, von dem Borne, P A, Willemze, R, Veelken, H, Falkenburg, J H F

“…The prognosis of adult patients with ALL remains unsatisfactory. AlloSCT is associated with a beneficial GVL response mediated by donor T cells. However, GVHD…”
Get full text

Impact of CR before and after allogeneic and autologous transplantation in multiple myeloma: results from the EBMT NMAM2000 prospective trial by Iacobelli, S, de Wreede, L C, Schönland, S, Björkstrand, B, Hegenbart, U, Gruber, A, Greinix, H, Volin, L, Narni, F, Carella, A M, Beksac, M, Bosi, A, Milone, G, Corradini, P, Friberg, K, van Biezen, A, Goldschmidt, H, de Witte, T, Morris, C, Niederwieser, D, Garderet, L, Kröger, N, Gahrton, G

“…Previous studies have shown that obtaining complete hematologic remission (CR) in multiple myeloma is an important predictor of PFS and OS. This applies both…”
Get full text

Hematopoietic stem cell transplantation in T-prolymphocytic leukemia: a retrospective study from the European Group for Blood and Marrow Transplantation and the Royal Marsden Consortium by Wiktor-Jedrzejczak, W, Dearden, C, de Wreede, L, van Biezen, A, Brinch, L, Leblond, V, Brune, M, Volin, L, Kazmi, M, Nagler, A, Schetelig, J, de Witte, T, Dreger, P

“…T-prolymphocytic leukemia (T-PLL) has a very poor prognosis with conventional immunochemotherapy. Incidental reports suggest that allogeneic hematopoietic stem…”
Get full text

Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party by Scheid, C, de Wreede, L, van Biezen, A, Koenecke, C, Göhring, G, Volin, L, Maertens, J, Finke, J, Passweg, J, Beelen, D, Cornelissen, J J, Itälä-Remes, M, Chevallier, P, Russell, N, Petersen, E, Milpied, N, Richard Espiga, C, Peniket, A, Sierra, J, Mufti, G, Crawley, C, Veelken, J H, Ljungman, P, Cahn, J Y, Alessandrino, E P, de Witte, T, Robin, M, Kröger, N

“…The International Prognostic Scoring System has been revised (IPSS-R) to predict prognosis of patients with myelodysplastic syndromes at diagnosis. To validate…”
Get full text

Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry by van Zeijl, M.C.T., de Wreede, L.C., van den Eertwegh, A.J.M., Wouters, M.W.J.M., Jochems, A., Schouwenburg, M.G., Aarts, M.J.B., van Akkooi, A.C.J., van den Berkmortel, F.W.P.J., de Groot, J.W.B., Hospers, G.A.P., Kapiteijn, E., Piersma, D., van Rijn, R.S., Suijkerbuijk, K.P.M., ten Tije, A.J., van der Veldt, A.A.M., Vreugdenhil, G., van der Hoeven, J.J.M., Haanen, J.B.A.G.

“…The treatment landscape has completely changed for advanced melanoma. We report survival outcomes and the differential impact of prognostic factors over time…”
Get full text

Donor T-cell responses and disease progression patterns of multiple myeloma by Eefting, M, de Wreede, L C, Von dem Borne, P A, Halkes, C J M, Kersting, S, Marijt, E W A, Putter, H, Veelken, H, Schetelig, J, Falkenburg, J H F

“…Donor T-cells transferred after allogeneic stem cell transplantation (alloSCT) can result in long-term disease control in myeloma by the graft-versus-myeloma…”
Get full text

Treatment of sporadic Burkitt lymphoma in adults, a retrospective comparison of four treatment regimens by Oosten, L. E. M., Chamuleau, M. E. D., Thielen, F. W., de Wreede, L. C., Siemes, C., Doorduijn, J. K., Smeekes, O. S., Kersten, M. J., Hardi, L., Baars, J. W., Demandt, A. M. P., Stevens, W. B. C., Nijland, M., van Imhoff, G. W., Brouwer, R., Uyl-de Groot, C. A., Kluin, P. M., de Jong, D., Veelken, H.

“…Burkitt lymphoma is an aggressive B cell malignancy accounting for 1–2% of all adult lymphomas. Treatment with dose-intensive, multi-agent chemotherapy is…”
Get full text

Prognostic pre-transplant factors in myelodysplastic syndromes primarily treated by high dose allogeneic hematopoietic stem cell transplantation: a retrospective study of the MDS subcommittee of the CMWP of the EBMT by Cremers, E. M. P., van Biezen, A., de Wreede, L. C., Scholten, M., Vitek, A., Finke, J., Platzbecker, U., Beelen, D., Schwerdtfeger, R., Volin, L., Harhalakis, N., Blijlevens, N., Nagler, A., Kröger, N., de Witte, T.

“…Many pre-transplant factors are known to influence the outcome of allogeneic stem cell transplantation (SCT) treatment in myelodysplastic syndromes (MDS)…”
Get full text

Donor lymphocyte infusions for the treatment of chronic myeloid leukemia relapse following peripheral blood or bone marrow stem cell transplantation by Basak, G W, de Wreede, L C, van Biezen, A, Wiktor-Jedrzejczak, W, Halaburda, K, Schmid, C, Schaap, N, Dazzi, F, von dem Borne, P A, Petersen, E, Beelen, D, Abayomi, A, Volin, L, Buzyn, A, Gurman, G, Bunjes, D, Guglielmi, C, Olavarria, E, de Witte, T

“…Peripheral blood used as a source of stem cells for transplantation (PBSCT) is known to exert stronger immune-mediated effects compared with BM (BMT). We…”
Get full text

P819: TRANSPLANT, TREATMENT AND TRANSFUSION FREE (TTT‐FREE) SURVIVAL AS RELEVANT CLINICAL ENDPOINT AFTER IMMUNOSUPPRESSIVE TREATMENT FOR ACQUIRED APLASTIC ANEMIA IN ADULTS by Koster, E., Halkes, C., Bogers, E., Hazenberg, C., Heubel‐Moenen, F., Langemeier, S., Meijer, E., Nur, E., Raaijmakers, M., Snijders, T., Witte, M., Tjon, J., Wreede, L.

Get full text